Alexander Kamb
Overview
Explore the profile of Alexander Kamb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh J, Kirsh C, Hsin J, Radecki K, Zampieri A, Manry D, et al.
iScience
. 2024 May;
27(6):109913.
PMID: 38799557
Here, we show that a NOT gated cell therapy (Tmod) can exploit antigens such as epidermal growth factor receptor (EGFR) and human leukocyte antigen-E (HLA-E) which are widely expressed on...
2.
Partin A, Bruno R, Shafaattalab S, Mause E, Winters A, Daris M, et al.
Front Immunol
. 2024 Feb;
15:1304765.
PMID: 38343543
Clinical applications of CAR-T cells are limited by the scarcity of tumor-specific targets and are often afflicted with the same on-target/off-tumor toxicities that plague other cancer treatments. A new promising...
3.
Tokatlian T, Asuelime G, Naradikian M, Mock J, Daris M, Martin A, et al.
Cancer Res Commun
. 2023 Mar;
2(1):58-65.
PMID: 36860694
Significance: We report an effort to generate high potency, selective CARs directed at mutant KRAS peptides. Although the heavily optimized CARs maintain high selectivity against wild-type KRAS, they lose selectivity...
4.
Mock J, Winters A, Riley T, Bruno R, Naradikian M, Sharma S, et al.
Mol Ther Oncolytics
. 2022 Nov;
27:157-166.
PMID: 36381658
Innovative cell-based therapies are important new weapons in the fight against difficult-to-treat cancers. One promising strategy involves cell therapies equipped with multiple receptors to integrate signals from more than one...
5.
DiAndreth B, Hamburger A, Xu H, Kamb A
Clin Immunol
. 2022 May;
241:109030.
PMID: 35561999
Immune cells that are engineered with receptors to integrate signals from multiple antigens offer a promising route to achieve the elusive property of therapeutic selectivity in cancer patients. Several types...
6.
Manry D, Bolanos K, DiAndreth B, Mock J, Kamb A
Front Immunol
. 2022 Apr;
13:826747.
PMID: 35359952
Progress toward improved solid-tumor treatment has long been hindered by the lack of truly tumor-specific targets. We have developed an approach to T cell therapy based on a dual-receptor system...
7.
Sandberg M, Wang X, Martin A, Nampe D, Gabrelow G, Li C, et al.
Sci Transl Med
. 2022 Mar;
14(634):eabm0306.
PMID: 35235342
The gene product [carcinoembryonic antigen (CEA)] is an attractive target for colorectal cancer because of its high expression in virtually all colorectal tumors and limited expression in most healthy adult...
8.
Tokatlian T, Asuelime G, Mock J, DiAndreth B, Sharma S, Toledo Warshaviak D, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35091455
Background: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a...
9.
Wang X, Wong L, McElvain M, Martire S, Lee W, Li C, et al.
Toxicol Appl Pharmacol
. 2022 Jan;
437:115894.
PMID: 35085592
Cell therapy is an emerging therapeutic modality with the power to exploit new cancer targets and potentially achieve positive outcomes for patients with few other options. Like all synthetic treatments,...
10.
Wang X, Sandberg M, Martin A, Negri K, Gabrelow G, Nampe D, et al.
J Immunother
. 2021 Aug;
44(8):292-306.
PMID: 34432728
Next-generation T-cell therapies will likely continue to utilize T-cell receptors (TCRs) and chimeric antigen receptors (CARs) because each receptor type has advantages. TCRs often possess exceptional properties even when tested...